Stock & Company Details
CervoMed Inc $CRVO
Price:
N/A
N/A
15M
$33M
52 Week High:
N/A
10 Day Average Volume:
N/A
-0.54
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
CRVO technical indicators
Latest CervoMed Inc (CRVO) indicator readings as of 2026-10-29.
CRVO's 14-day RSI is 26.5, in oversold territory. At $1.75 it is trading 50.5% below its 200-day moving average of $3.54, and below its 50-day average of $2.57. Price sits near the lower Bollinger Band ($1.60 to $3.48). ADX reads 26.0, indicating a trending market.
Overview
diffusion pharmaceuticals is a clinical stage company focused on improving the effectiveness of standard-of-care therapies for life-threatening treatment-resistant solid cancerous tumors, without adding harmful side effects. the company is developing its lead drug, trans sodium crocetinate (tsc), which has received orphan drug designation from the fda for use in a number of cancers in which tumor hypoxia (oxygen deprivation) diminishes the efficacy of current treatments. tsc targets the cancer’s hypoxic micro-environment, re-oxygenating treatment-resistant tissue and making the cancerous cells more vulnerable to the therapeutic effects of conventional radiation and chemotherapy. the company is poised to begin a pivotal phase 3 trial in glioblastoma (gbm) in 2016. other programs include planned phase 2/3 trials in pancreatic cancer and brain metastases. because tsc’s novel mechanism safely re-oxygenates a wide range of tumor types, its use is not limited to a specific tumor tissue, but
Finance Bot
Ask your questions
Start by typing a question below.
